Financials·Mortgage REITs·$16.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.88 | N/A | -238.15% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.88 | N/A | -238.15% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions affecting profitability. They did not provide a clear outlook for future performance.
Management did not provide specific insights into revenue performance.
The company acknowledged challenges impacting earnings.
Annalay Capital Management's significant EPS miss indicates ongoing challenges in their operations. The stock reacted negatively, dropping 1.75%, reflecting investor concerns about the company's financial health. Without guidance or revenue figures, uncertainty remains about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERTEX PHARMACEUTICA
Feb 5, 2024